Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing

Natalia Buenache, Marta Lasa, Andrés Arroyo, Carmen González, Larissa Haertle, Yanira Ruiz‐Heredia, Rosa Ayala, Rafael Alonso, Alejandro Martín‐Muñoz, Juan M Rosa‐Rosa, Verónica González, María J Calasanz, Paula Rodríguez‐Otero, Laura Rosiñol, Felipe De Arriba, Enrique M Ocio, Albert Oriol, Yolanda González, Anna Sureda, Sunil Lakhwani, María E Clavero, Angela Ibáñez, Clara Gómez, Alberto Orfao, María‐Victoria Mateos, Juan J Lahuerta, María T Cedena, Joan Bladé, Jesús San Miguel, Noemi Puig, Bruno Paiva, Joaquín Martínez‐López · 2026

Read Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing by Natalia Buenache, Marta Lasa, Andrés Arroyo, Carmen González, Larissa Haertle, Yanira Ruiz‐Heredia, Rosa Ayala, Rafael Alonso, Alejandro Martín‐Muñoz, Juan M Rosa‐Rosa, Verónica González, María J Calasanz, Paula Rodríguez‐Otero, Laura Rosiñol, Felipe De Arriba, Enrique M Ocio, Albert Oriol, Yolanda González, Anna Sureda, Sunil Lakhwani, María E Clavero, Angela Ibáñez, Clara Gómez, Alberto Orfao, María‐Victoria Mateos, Juan J Lahuerta, María T Cedena, Joan Bladé, Jesús San Miguel, Noemi Puig, Bruno Paiva, Joaquín Martínez‐López (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13278021.txt.

Description

Natalia Buenache leads a 2026 study of a blood test for leftover cancer cells in multiple myeloma, a cancer of plasma cells in bone marrow. Checking bone marrow for residual disease predicts outcomes but is invasive and can miss patchy disease. The team tested a sensitive DNA sequencing method on cell-free DNA in blood from 84 trial patients, using 292 samples over time.

Detectable tumor DNA in blood predicted relapse more accurately than the standard bone marrow flow test, with far fewer false alarms. Patients with detectable DNA faced a much higher risk of progression or death. Automated sample preparation matched manual methods. A blood-based check could make repeated monitoring easier, the authors propose.

Catalog record

CREATORNatalia Buenache, Marta Lasa, Andrés Arroyo, Carmen González, Larissa Haertle, Yanira Ruiz‐Heredia, Rosa Ayala, Rafael Alonso, Alejandro Martín‐Muñoz, Juan M Rosa‐Rosa, Verónica González, María J Calasanz, Paula Rodríguez‐Otero, Laura Rosiñol, Felipe De Arriba, Enrique M Ocio, Albert Oriol, Yolanda González, Anna Sureda, Sunil Lakhwani, María E Clavero, Angela Ibáñez, Clara Gómez, Alberto Orfao, María‐Victoria Mateos, Juan J Lahuerta, María T Cedena, Joan Bladé, Jesús San Miguel, Noemi Puig, Bruno Paiva, Joaquín Martínez‐López
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48940
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13278021

Browse the full library · About the Tower of Babel